 Numerous treatment options are available to HIV infected patients who are antiretroviral ARV therapy naive, but an optimal regimen has not yet been established. This study will compare a nonnucleoside reverse transcriptase inhibitor NNRTI-based regimen, a ritonavir RTV-enhanced protease inhibitor PI-based regimen, and a nucleoside reverse transcriptase inhibitor NRTI-sparing regimen for the initial treatment of HIV infection. 